This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GSK649868, GW649868
Description: GW649868 is an orexin antagonist. The orexins (hypocretins) are a peptide family comprised of two peptides, hypocretin-1 and hypocretin-2. Recent observations suggest an involvement of these peptides in the regulation of behavioral state. For example, these peptides are found in a variety of brain regions associated with the regulation of forebrain neuronal and behavioral activity states.
Deal Structure: This drug was discovered by GSK based on Human Genome Sciences technology. Human Genome Sciences is entitled to receive a milestone payment if the compound moves through clinical development into registration. Human Genome Scienes is also entitled to worldwide royalties of up to 10% if this compound is commercialized, and also has a 20% co-promotion option in North America and Europe.
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.
Additional information available to subscribers only: